Fitzgerald Joseph Michael 4
4 · BOSTON SCIENTIFIC CORP · Filed Nov 4, 2025
Insider Transaction Report
Form 4
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
Transactions
- Sale
Common Stock
2025-11-03$100.75/sh−3,600$362,693→ 224,742 total - Sale
Common Stock
2025-11-03$99.76/sh−16,928$1,688,749→ 207,814 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-03−50,000→ 0 totalExercise: $26.15Exp: 2027-12-01→ Common Stock (50,000 underlying) - Exercise/Conversion
Common Stock
2025-11-03$26.15/sh+50,000$1,307,500→ 228,342 total - Sale
Common Stock
2025-11-03$99.14/sh−29,472$2,921,895→ 178,342 total
Holdings
- 5,234(indirect: By Children)
Common Stock
Footnotes (6)
- [F1]The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.
- [F2]Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $100.72 to $100.80, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $99.59 to $100.53, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $98.57 to $99.54, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F5]The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
- [F6]Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant.